The impact of rare and low-frequency genetic variants in common disease by Lorenzo Bomba, Klaudia Walter, Nicole Soranzo

“…Here we review experimental approaches and current knowledge on the contribution of these genetic variants in complex disease and discuss challenges and opportunities for personalised medicine.…”
Get full text

Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved] by Simon van Rij, Peter Gilling

“…In 2015, the use of personalised medicine is tailoring treatment to individual patient needs and to genetic characteristics. …”
Get full text

Warfarin: The End or the End of One Size Fits All Therapy? by Munir Pirmohamed

Get full text

Biological variation: Understanding why it is so important? by Tony Badrick

“…The current phase of BV integration into practice is using Patient-Based Real-Time Quality Control (PBRTQC) and Patient Based Quality Assurance (PBQA) to detect a change in assay performance.The challenge of personalised medicine is to determine an individual reference interval. …”
Get full text

Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. by Singh, I, Naci, H, Miller, J, Caplan, A, Cipriani, A

“…We argue that measurable ethical obligations to patients should form the core of future comparative effectiveness research in an era of personalised medicine. …”

Picking the winners: Outcome prediction in pleural disease by Corcoran, J, Rahman, N

“…Furthermore, the range of diagnostic and therapeutic interventions available to patients with pleural disease and their physicians [ref] means that identifying those individuals most likely to benefit from a particular treatment is becoming ever more important in an era of personalised medicine. …”

Precision medicine in the management of type 2 diabetes by Gloyn, A, Drucker, D

“…We contrast the success in delivering personalised medicine for monogenic diabetes with the greater challenge of providing a precision medicine approach for type 2 diabetes, highlighting gaps, limitations, and areas requiring further study.…”

Introduction to the article collection 'Translation in healthcare: ethical, legal, and social implications'. by Morrison, M, Dickenson, D, Lee, S

“…New technologies are transforming and reconfiguring the boundaries between patients, research participants and consumers, between research and clinical practice, and between public and private domains. From personalised medicine to big data and social media, these platforms facilitate new kinds of interactions, challenge longstanding understandings of privacy and consent, and raise fundamental questions about how the translational patient pathway should be organised.This editorial introduces the cross-journal article collection "Translation in healthcare: ethical, legal, and social implications", briefly outlining the genesis of the collection in the 2015 Translation in healthcare conference in Oxford, UK and providing an introduction to the contemporary ethical challenges of translational research in biology and medicine accompanied by a summary of the papers included in this collection.…”

Fighting Cancer around the World: A Framework for Action by Denis Horgan, Rizwana Mia, Tosan Erhabor, Yosr Hamdi, Collet Dandara, Jonathan A. Lal, Joel Fokom Domgue, Oladimeji Ewumi, Teresia Nyawira, Salomé Meyer, Dominique Kondji, Ngiambudulu M. Francisco, Sadakatsu Ikeda, Chai Chuah, Roselle De Guzman, Anupriya Paul, Krishna Reddy Nallamalla, Woong-Yang Park, Vijay Tripathi, Ravikant Tripathi, Amber Johns, Mohan P. Singh, Maude E. Phipps, France Dube, Kate Whittaker, Deborah Mukherji, Hadi Mohamad Abu Rasheed, Marta Kozaric, Joseph A. Pinto, Stephen Doral Stefani, Federico Augustovski, Maria Eugenia Aponte Rueda, Ricardo Fujita Alarcon, Hugo A. Barrera-Saldana

“…A series of panels have been organized by the European Alliance for Personalised Medicine (EAPM) to identify different aspects of cancer care around the globe. …”
Get full text

The Role of the European Pharmacopoeia (Ph Eur) in Quality Control of Traditional Chinese Herbal Medicine in European Member States by Mei Wang, Gerhard Franz

Get full text

Alloys-By-Design: a low-modulus titanium alloy for additively manufactured biomedical implants by Alabort, E, Tang, YT, Barba, D, Reed, RC

“…Due to the interest in alloys for personalised medicine, additive manufacturability is also considered: compositions with low cracking susceptibility and with propensity for non-planar growth are identified. …”

Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. by Ulahannan, D, Kovac, M, Mulholland, P, Cazier, J, Tomlinson, I

“…Paradoxically, NGS may simply move the bottleneck of personalised medicine from data acquisition to the identification of reliable biomarkers. …”

Cancer-associated membrane protein as targeted therapy for bladder cancer by Roslan, Adlina, Sulaiman, Nurshahira, Mohd Ghani, Khairul Asri, Nurdin, Armania

“…This review describes studies on membrane proteins as potential biomarkers to facilitate personalised medicine. It aims to introduce and discuss the types and significant functions of membrane proteins as potential biomarkers for future medicine. …”

HGCA2.0: An RNA-Seq Based Webtool for Gene Coexpression Analysis in <i>Homo sapiens</i> by Vasileios L. Zogopoulos, Apostolos Malatras, Konstantinos Kyriakidis, Chrysanthi Charalampous, Evanthia A. Makrygianni, Stéphanie Duguez, Marianna A. Koutsi, Marialena Pouliou, Christos Vasileiou, William J. Duddy, Marios Agelopoulos, George P. Chrousos, Vassiliki A. Iconomidou, Ioannis Michalopoulos

Get full text

Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19 by Magda Bucholc, Declan Bradley, Damien Bennett, Lynsey Patterson, Rachel Spiers, David Gibson, Hugo Van Woerden, Anthony J. Bjourson

Get full text

Unblocking Blockbusters: Using Boolean Text-Mining to Optimise Clinical Trial Design and Timeline for Novel Anticancer Drugs by Richard J. Epstein

“…Using scenarios relating to oncology, it is shown that rapid data-mining of the scientific literature can refine therapeutic hypotheses and thus reduce empirical reliance on preclinical model development and early-phase clinical trials. Moreover, as personalised medicine evolves, this approach may inform biomarker-guided phase III trial strategies for noncytotoxic (antimetastatic) drugs that prolong patient survival without necessarily inducing tumor shrinkage. …”
Get full text

A multifunctional 3D co-culture system for studies of mammary tissue morphogenesis and stem cell biology. by Jonathan J Campbell, Natalia Davidenko, Maria M Caffarel, Ruth E Cameron, Christine J Watson

“…Importantly, this culture system recapitulates the stem cell niche as primary mammary stem cells form complex organoids, emphasising the utility of this approach for developmental and tumorigenic studies using genetically altered animals or human biopsy material, and for screening cancer therapeutics for personalised medicine.…”
Get full text

Pharmacogenomics: an opportunity for personalised psychotropic prescribing in adults with intellectual disabilities by Bhathika Perera, Charles Steward, Ken Courtenay, Timothy Andrews, Rohit Shankar

“…Understanding how genetic variations affect medications is a step towards personalised medicine. This may improve personalised prescribing for people with intellectual disabilities, especially given the high rate of psychiatric and behavioural problems in this population. …”
Get full text

Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults by Marie-Christine Dombret, Khuder Alagha, Louis Philippe Boulet, Pierre Yves Brillet, Guy Joos, Michel Laviolette, Renaud Louis, Thierry Rochat, Paola Soccal, Michel Aubier, Pascal Chanez

“…Bronchial thermoplasty fits in perfectly with the movement to expand personalised medicine in the field of chronic airway disorders. …”
Get full text

Predicting synthetic lethal interactions using conserved patterns in protein interaction networks. by Graeme Benstead-Hume, Xiangrong Chen, Suzanna R Hopkins, Karen A Lane, Jessica A Downs, Frances M G Pearl

“…This is facilitating personalised medicine strategies in cancers where specific tumour suppressors have become inactivated. …”
Get full text